These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20492887)

  • 61. Conversion to positive tuberculosis test during etanercept treatment of psoriasis.
    Sumner W; Feldman SR
    J Drugs Dermatol; 2007 Oct; 6(10):1048. PubMed ID: 17966185
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Leukemic phase of follicular lymphoma after treatment with etanercept in a patient with psoriasis.
    Ganguly S
    Am J Clin Dermatol; 2009; 10(2):125-6. PubMed ID: 19222252
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis.
    Comte C; Guilhou JJ; Guillot B; Dereure O
    Dermatology; 2008; 217(3):284-5. PubMed ID: 18688171
    [No Abstract]   [Full Text] [Related]  

  • 64. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.
    Chiu HY; Hsueh PR; Tsai TF
    Br J Dermatol; 2011 Mar; 164(3):553-9. PubMed ID: 21083541
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature.
    Mahil SK; Andrews TC; Brierley C; Barker JN; Smith CH
    J Dermatolog Treat; 2013 Feb; 24(1):38-49. PubMed ID: 22268700
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Combined therapy with etanercept and systemic drugs or phototherapy].
    Belinchón I; Ballester I
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():40-4. PubMed ID: 20492879
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
    Shmidt E; Wetter DA; Ferguson SB; Pittelkow MR
    J Am Acad Dermatol; 2012 Nov; 67(5):e179-85. PubMed ID: 21752492
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Is etanercept safe for treating plaque psoriasis in a patient with chronic hepatitis C virus infection?
    Gandhi RK; Pickup T; Sheth PB
    Arch Dermatol; 2010 Oct; 146(10):1151-2. PubMed ID: 20956650
    [No Abstract]   [Full Text] [Related]  

  • 70. Atypical carcinoid tumor of the thymus with ectopic ACTH production developed during the course of etanercept treatment--case report.
    Simsek I; Pay S; Dinc A; Erdem H; Kurt B
    Clin Rheumatol; 2007 Sep; 26(9):1561-2. PubMed ID: 17061154
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy of etanercept for the treatment of psoriasis: an overview of the Italian clinical experience from the real-life setting and independent studies.
    Vena GA; Cassano N; Piaserico S; Conti A; Girolomoni G
    Immunopharmacol Immunotoxicol; 2012 Dec; 34(6):901-6. PubMed ID: 22686544
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Etanercept therapy for psoriasis in a patient with active pulmonary tuberculosis.
    Huo R; Romanelli P
    Am J Clin Dermatol; 2010; 11 Suppl 1():39-40. PubMed ID: 20586506
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Etanercept].
    Sparsa A
    Ann Dermatol Venereol; 2005 Nov; 132(11 Pt 1):861-76. PubMed ID: 16327716
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
    Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
    Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasis.
    Esposito M; Gisondi P; Cassano N; Babino G; Cannizzaro MV; Ferrucci G; Chimenti S; Giunta A
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S31-4. PubMed ID: 25381971
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Acute myelogenous leukemia in a patient receiving etanercept for psoriasis.
    Bachmeyer C; Thiolière B; Khosrotehrani K; Cattan E
    J Am Acad Dermatol; 2007 Jan; 56(1):169-70. PubMed ID: 17190640
    [No Abstract]   [Full Text] [Related]  

  • 77. Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-a inhibitors.
    Chen M; Holland MJ; Mir MR; Wong MG; Kelley BP; Grim KD; Bhuchar SS; Hsu S
    J Drugs Dermatol; 2011 Mar; 10(3):280-4. PubMed ID: 21369645
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.
    Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
    J Dermatol Sci; 2014 Dec; 76(3):180-5. PubMed ID: 25306295
    [TBL] [Abstract][Full Text] [Related]  

  • 79. TNF-α antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis.
    Saraceno R; Pietroleonardo L; Mazzotta A; Zangrilli A; Bianchi L; Chimenti S
    Expert Opin Biol Ther; 2013 Apr; 13(4):469-73. PubMed ID: 23157654
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Observational case series on a group of psoriasis patients who failed to respond to any TNF blockers.
    Viguier M; Livideanu C; Beylot-Barry M; Richard MA; Paul C; Bachelez H; Aubin F;
    J Dermatolog Treat; 2014 Feb; 25(1):75-7. PubMed ID: 23724854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.